Sorry, this activity has expired and is no longer available for CME credit. You may still enjoy the program.
CME Information
Provider Statement: This continuing medical education activity is provided by 
.
Support Statement: This activity is supported by an educational grant from Genentech, Inc. and Merck & Co., Inc.
Target Audience: The intended audience for this activity is medical oncologists, radiation oncologists, and other health care professionals involved in the treatment of patients with NSCLC.
Learning Objectives: Upon successful completion of this educational activity, participants should be better able to:
- Examine the latest advances in planning, delivery accuracy, and normal tissue sparing radiotherapy for patients with NSCLC.
- Assess new evidence about the molecular characterization of NSCLC, optimizing treatment, and managing side effects in individual patients.
- Describe new clinical data and findings relevant to the utility of novel therapeutic modalities for the treatment of NSCLC
Activity Chair:
Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Director, Thoracic Oncology Research Program
Associate Director for Translational Research
Translational Research Program
Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, CT
Faculty:
Walter J. Curran, Jr. MD
Executive Director
Winship Cancer Institute of Emory University
Atlanta, Georgia
Naiyer A. Rizvi, MD
Director
Thoracic Oncology & Phase I Immunotherapeutics
Columbia University Medical Center
New York, NY
Fred R. Hirsch, MD, PhD
Professor of Medicine and Pathology
Pia and Fred R. Hirsch Endowed Chair in Lung Cancer
University of Colorado Cancer Center
CEO, International Association for the Study of Lung Cancer (IASLC)
Aurora, CO
Reviewers:
Joel W. Neal, MD, PhD
Ronald A. Codario, MD, FACP, FNLA, CCMEP
Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 1.0AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, November 10, 2015, through November 9, 2016.
How to participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the case and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Activity Chair and Faculty member relationship(s):
Roy S. Herbst, MD, PhD
Served as an advisor or consultant for: Biothera, Diatech, Genentech/Roche, Gilead, Kolltan, Merck, N of 1, Pfizer
Received grants for clinical research from: Genentech
Walter J. Curran, Jr. MD
Consulting Fees: AstraZeneca, Bristol-Myers Squibb
Contracted Research: AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Millennium
Ownership Interest: Eviti
Naiyer A. Rizvi, MD
Consulting Fees: AstraZeneca, Bristol-Myers Squibb, Merck, Roche
Fred R. Hirsch, MD, PhD
Consulting Fees: AstraZeneca, Bristol-Myers Squibb, Celgene, Genentech, Lilly, Pfizer, Novartis
Reviewers report the following relationship(s):
Joel W. Neal, MD, PhD
Consulting Fee: CARET Physicians Resource Management, Clovis Oncology, Nektar Therapeutics
Contract Research: ArQule, Boehringer Ingelheim, Exelixis, Genentech/Roche, Merck, Nektar Therapeutics, Novartis
Ronald A. Codario, MD, FACP, FNLA, CCMEP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2015 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com